Amundi
KRYS icon

Amundi’s Krystal Biotech KRYS Stock Holding History

Amundi’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47M Buy
5,706
+1,952
+52% +$519K ﹤0.01% 1176
2025
Q4 		$926K Sell
3,754
-807
-18% -$170K ﹤0.01% 1289
2025
Q3 		$824K Buy
4,561
+367
+9% +$54.9K ﹤0.01% 1203
2025
Q2 		$593K Buy
+4,194
New +$616K ﹤0.01% 1330
2022
Q4 		– Sell
-1,762
Closed -$123K – 1943
2022
Q3 		$123K Hold
1,762
– – ﹤0.01% 1526
2022
Q2 		$126K Buy
+1,762
New +$110K ﹤0.01% 1415

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi's KRYS Position: Q1 2026 in Review

Amundi increased its Krystal Biotech (KRYS) stake by 52% in Q1 2026, buying an estimated $519K and bringing the position to 5,706 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1176.

Amundi first reported a position in KRYS in Q2 2022 and has held it in 6 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Amundi held 5,706 shares of Krystal Biotech worth $1.47M as of Q1 2026.
  • Amundi bought 1,952 Krystal Biotech shares in Q1 2026, an estimated $519K.
  • Krystal Biotech made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1176 holding.
  • Amundi first reported a position in Krystal Biotech in Q2 2022 and has held it in 6 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.